Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785883 | Cancer Treatment Reviews | 2018 | 28 Pages |
Abstract
According to the first published data, immunotherapy has shown promising results in the management of recurrent and metastatic (r/m) HNSCC. Anti-PD-1 blockers have been recently approved by US and EU regulatory agencies in this setting. The encouraging results in r/m HNSCC prompted the incorporation of this approach also in the treatment of locally advanced disease. However, the strategies for the rational and evidence-based combinations to maximize clinical benefit are only starting to emerge. In this view, knowing in depth the specific properties of HNSCC and the underlying immunological conditions of the bearing hosts is an essential step. The role of immune system in the development and the management of HNSCC, the main mechanisms of tumor escape and the most recent results from clinical trials will be discussed herein.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Stefano Cavalieri, Licia Rivoltini, Cristiana Bergamini, Laura D. Locati, Lisa Licitra, Paolo Bossi,